This biotech just raised $25M to develop plant-based gel that stops traumatic bleeding in seconds
InnovationRx: Healthcare’s 2023 Outlook, Covid Hospitalizations Are Rising And What To Know About RSV
Interview: 17-year-old invents life-saving gel technology
When he was 17 years old, Joe Landolina created a revolutionary gel. Now, he is 29 years old and co-founder and CEO of Cresilon, his homegrown Brooklyn-based biotech company that recently submitted the gel for FDA 510(k) clearance for human use and raised $38.5 million in Series A3 financing last year. DDW’s Megan Thomas caught up with Landolina about his success story.
How This Plant-Based Gel Can Treat Wounds
Cresilon Closes $25 Million in Series A-4 Financing to Accelerate Global Expansion and Bring Revolutionary Hemostatic Gel to Human Health Market
Cresilon and Walter Reed Army Institute of Research Sign Cooperative R&D Agreement for Treatment of Traumatic Brain Injuries
“Cresilon is extremely proud and honored to be supporting the DoD and WRAIR in this critically important work,” said Joe Landolina, CEO of Cresilon. “This collaboration is a testament to the potential of our technology, and we are truly hopeful that it can make a difference in the treatment of TBI and in the precious lives of our soldiers.”
Subscribe to our Newsletter
Stay in touch with us to get Cresilon’s news, investment opportunities, and product releases.